Literature DB >> 29188452

Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells.

Jun Zhang1, Jaesuh Park1, Jung-Woo Lee2, Yong-Dae Kwon3, Eun-Cheol Kim4.   

Abstract

OBJECTIVES: Although bisphosphonates (BPs) are known to be associated with osteonecrosis of the maxilla, the precise effects of BPs on bone metabolism in human maxillary sinus mucosal cells (HMSMCs) are not yet known. The purposes of this study were to examine the effects of the BPs zoledronate (ZOL) and alendronate (ALN) on osteoblastic and osteoclastic differentiation in HMSMCs and to investigate the signaling pathways involved.
MATERIALS AND METHODS: The effects of ZOL and ALN were assessed for osteoblast differentiation by alkaline phosphatase (ALP) activity, alizarin red staining, and RT-PCR for genes encoding Runx2 and osterix. Receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow macrophages (BMMs) was also examined.
RESULTS: ZOL and ALN both suppressed osteoblastic differentiation, as evidenced by their effects on ALP activity, mineralization nodule formation, and the mRNA expression levels of osteoblastic transcript factors. The RANKL/osteoprotegerin ratio in HMSMCs was increased by ALN, whereas ZOL had the opposite effect. Conditioned medium obtained from ALN-treated HMSMCs stimulated osteoclast formation and upregulated NFATc1 expression, whereas conditioned medium from ZOL-treated cells did not. ALN was more cytotoxic and stimulated apoptosis more strongly than ZOL. BPs decreased the protein levels of the non-canonical Wnt signaling protein Wnt5a and calmodulin-dependent kinase II. Moreover, recombinant human Wnt5a reversed the effects of BPs on osteoblastic and osteoclastic differentiation.
CONCLUSION: This study is the first demonstration that BPs exert negative effects on osteoblastic and osteoclastic processes via the non-canonical Wnt pathway in HMSMSCs. CLINICAL RELEVANCE: It suggests that patients taking BPs during the period of maxillary sinus lifting and amentation should be given special attention.

Entities:  

Keywords:  Bisphosphonates; Differentiation; Maxillary sinus mucosa-derived stem cells; Osteoblast; Osteoclast; Wnt5a

Mesh:

Substances:

Year:  2017        PMID: 29188452     DOI: 10.1007/s00784-017-2291-z

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  51 in total

1.  Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.

Authors:  A M Pabst; M Krüger; T Ziebart; C Jacobs; C Walter
Journal:  Clin Oral Investig       Date:  2015-01-16       Impact factor: 3.573

2.  Alendronate induces mineralization in mouse osteoblastic MC3T3-E1 cells: regulation of mineralization-related genes.

Authors:  Y Inoue; I Hisa; S Seino; H Kaji
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-03-08       Impact factor: 2.949

3.  Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giuseppe Avvisati; Giordano Dicuonzo; Fabrizio Battistoni; Michele Gavasci; Alfredo Salerno; Vincenzo Denaro; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

4.  Alendronate therapy may be effective in the prevention of bone loss around titanium implants inserted in estrogen-deficient rats.

Authors:  Poliana Mendes Duarte; Bruno César de Vasconcelos Gurgel; Antonio Wilson Sallum; Getúlio Rocha Nogueira Filho; Enilson Antonio Sallum; Francisco Humberto Nociti
Journal:  J Periodontol       Date:  2005-01       Impact factor: 6.993

Review 5.  The role of p53 in apoptosis.

Authors:  Joana D Amaral; Joana M Xavier; Clifford J Steer; Cecília M Rodrigues
Journal:  Discov Med       Date:  2010-02       Impact factor: 2.970

6.  Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

Authors:  Volker Viereck; Günter Emons; Vanessa Lauck; Karl-Heinz Frosch; Sabine Blaschke; Carsten Gründker; Lorenz C Hofbauer
Journal:  Biochem Biophys Res Commun       Date:  2002-03-01       Impact factor: 3.575

7.  Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro.

Authors:  M F Moreau; C Guillet; P Massin; S Chevalier; H Gascan; M F Baslé; D Chappard
Journal:  Biochem Pharmacol       Date:  2006-11-03       Impact factor: 5.858

Review 8.  Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report.

Authors:  Pongthorn Narongroeknawin; Maria I Danila; Lewis G Humphreys; Andrei Barasch; Jeffrey R Curtis
Journal:  Spec Care Dentist       Date:  2010 Mar-Apr

9.  Oral bisphosphonates and dental implants: a retrospective study.

Authors:  Brian M Bell; Robert Edward Bell
Journal:  J Oral Maxillofac Surg       Date:  2008-05       Impact factor: 1.895

10.  Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation.

Authors:  Jun Yamada; Nelson H Tsuno; Joji Kitayama; Takeshi Tsuchiya; Satomi Yoneyama; Masahiro Asakage; Yurai Okaji; Yasutaka Shuno; Takeshi Nishikawa; Junichiro Tanaka; Koki Takahashi; Hirokazu Nagawa
Journal:  J Surg Res       Date:  2008-02-29       Impact factor: 2.192

View more
  3 in total

1.  Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.

Authors:  Xiao-Lin Huang; Chao Liu; Xue-Mei Shi; Yu-Ting Cheng; Qian Zhou; Jian-Ping Li; Jian Liao
Journal:  Mol Med Rep       Date:  2021-12-22       Impact factor: 2.952

Review 2.  How zoledronic acid improves osteoporosis by acting on osteoclasts.

Authors:  Biao Wang; Yi Zhan; Liang Yan; Dingjun Hao
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

Review 3.  Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.

Authors:  Lianwei Wang; Dengyang Fang; Jinming Xu; Runlan Luo
Journal:  BMC Cancer       Date:  2020-11-03       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.